Craig N Zimmerman

This inventor holds 37 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Radiopharmaceuticals. Top assignees: Molecular Insight Pharmaceuticals, Inc., Biogen, Incorporated, Biogen Idec Ma Inc.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Craig N Zimmerman. Retrieved from https://idiyas.com/inventor/craig-n-zimmerman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 4)

% Patents Active = 75.7

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 4.8

ph-index = 13

Forward Citations = 684(Granted Patents)

Location History:

Somerville, MA (US) (2001 - 2006)
Cambridge, MA (US) (2013 - 2020)
Topsfield, MA (US) (2001 - 2023)

Company Filing History:

25 out of 41

Molecular Insight Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticlas, Inc.

patent

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Radiopharmaceuticals

Dendrimers

Glutamic Acid

Carbonic Anhydrase IX

PSMA Inhibitors

Technetium Complexes

Rhenium Complexes

Indole Compounds

CRTH2 Modulators

Cell Adhesion Inhibitors

Heterodimers

Radioimaging Agents

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534429 - Heterodimers of glutamic acid (2026-01-27),

2. 11712485 - Triazine based radiopharmaceuticals and radioimaging agents (2023-08-01),

3. 10898598 - Triazine based radiopharmaceuticals and radioimaging agents (2021-01-26),

4. 10647666 - Heterodimers of glutamic acid (2020-05-12),

5. 10640461 - Heterodimers of glutamic acid (2020-05-05),

6. 10201624 - Triazine based radiopharmaceuticals and radioimaging agents (2019-02-12),

7. 10131627 - Heterodimers of glutamic acid (2018-11-20),

8. 10086096 - Triazine based radiopharmaceuticals and radioimaging agents (2018-10-02),

9. 9878980 - Heterodimers of glutamic acid (2018-01-30),

10. 9687572 - PSMA-targeted dendrimers (2017-06-27),

11. 9447121 - Triazine based radiopharmaceuticals and radioimaging agents (2016-09-20),

12. 9433594 - Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof (2016-09-06),

13. 9422251 - Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX (2016-08-23),

14. 9388144 - Radiolabeled prostate specific membrane antigen inhibitors (2016-07-12),

15. 9309193 - Heterodimers of glutamic acid (2016-04-12),

Title: Innovations of Craig N. Zimmerman in Radiopharmaceuticals

Introduction

Craig N. Zimmerman, based in Cambridge, Massachusetts, is a distinguished inventor with an impressive portfolio of 36 patents. His work primarily focuses on advancements in radiopharmaceuticals, contributing to significant innovations in medical imaging and therapies.

Latest Patents

Among his latest patented innovations are "Triazine based radiopharmaceuticals and radioimaging agents," which highlight the development of metal complexes that include a radionuclide, along with compounds denoted as Formula I and Formula II. These innovations serve as potent inhibitors of the Prostate-Specific Membrane Antigen (PSMA), showcasing Zimmerman's commitment to enhancing the field of nuclear medicine.

Career Highlights

Craig has made notable contributions while working at companies such as Molecular Insight Pharmaceuticals, Inc. and Biogen, Incorporated. His tenure at these organizations has enriched his expertise and has propelled his innovations forward, further solidifying his position in the field of biopharmaceutical development.

Collaborations

Throughout his career, Zimmerman has collaborated with prominent individuals in the industry, including John W. Babich and John L. Joyal. These collaborations have allowed for a fusion of ideas, leading to the successful development of impactful medical solutions.

Conclusion

Craig N. Zimmerman's contributions to the field of radiopharmaceuticals are significant and continue to evolve. With a wealth of patents and a strong collaborative network, he remains a key figure in driving innovations that improve medical imaging and treatment options. As the industry advances, his work will undoubtedly contribute to further breakthroughs in healthcare technologies.

Profile summary based on public USPTO records.